Rapid Rx Quiz: COVID-19 Treatment Updates

Mary L. Windle, PharmD


August 22, 2023

The antiviral medication, remdesivir, remains effective against Omicron subvariants, including XBB. However, no monoclonal antibodies (eg, casirivimab-imdevimab, tixagevimab-cilgavimab, sotrovimab, bebtelovimab) are effective against Omicron subvariants XBB. As of August 5, 2023, XBB variants accounted for almost 80% of cases in the United States. The EG.5 variant has increased and accounts for 17% of cases.

Learn more about remdesivir.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.